Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroblastoma × Isotretinoin × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 35 Sarcoma 1 Other hematologic neoplasm 1 NET 1 Lymphoid 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1 Neuroblastoma 1

Interventions

gallium Ga 68 dotatate 3 fluorodopa F 18 2 Magnetic Resonance Spectroscopy 2 pertuzumab 1 pentetreotide 1 arginyllysine 1 Whole Body Imaging 1 Tretinoin 1 Nivolumab 1 Isotretinoin 1 Furosemide 1 Erlotinib Hydrochloride 1 Amino Acids 1 90Y-octreotide, DOTA-Tyr(3)- 1 4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1 3-fluorobenzylguanidine 1 (18F)GTP1 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01048086 2016-06-21

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

University of Iowa

Phase 2 Withdrawn

CNSEndocrineNET

Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡